Browsing Tag
Amgen
48 posts
Daiichi Sankyo launches development of oral triple combination tablets for LDL cholesterol management in Europe
Daiichi Sankyo (TYO: 4568) begins developing oral triple therapy with bempedoic acid, ezetimibe, and statins to transform LDL cholesterol management in Europe.
Top 5 PCSK9 inhibitor stocks to watch in 2025: From injectables to gene editing
Explore the top five PCSK9 inhibitor stocks—Amgen, Regeneron–Sanofi, Merck, Novartis, Verve—and what makes each a standout in cholesterol treatment in 2025.
Biotech layoffs 2025: Prothena joins the wave—What’s driving the restructuring trend?
Explore why Prothena’s layoffs reflect a growing 2025 biotech downsizing trend. What’s causing the wave, and who might be next?
Amgen and Kyowa Kirin see breakthrough in rocatinlimab Phase 3 Trial, eyes on FDA path
Amgen and Kyowa Kirin have reported positive top-line results from the Rocatinlimab Phase 3 IGNITE trial, part of…
Amgen and AstraZeneca’s Tezspire achieves key milestone in Phase 3 nasal polyps trial
Amgen and AstraZeneca have revealed promising results from the Phase 3 Waypoint trial, demonstrating that Tezspire (tezepelumab-ekko) delivers…
Amgen reports strong Q4 growth amid expanding product sales and biotech innovations
Amgen’s revenue growth for the fourth quarter of 2024 exceeded analyst expectations, reflecting the company’s expanding biopharmaceutical portfolio…
Amgen’s Blincyto gains EU approval for consolidation phase treatment in B-ALL
Amgen has received European Commission approval for Blincyto (blinatumomab) as part of consolidation therapy in adults with newly…
FDA approves Amgen’s BLINCYTO for expanded use in B-ALL treatment
Amgen (NASDAQ: AMGN) has achieved a significant milestone with the recent U.S. Food and Drug Administration (FDA) approval…
COURSE trial reveals promising results for TEZSPIRE in COPD patients with high eosinophil counts
In a significant development in chronic obstructive pulmonary disease (COPD) management, the Phase IIa COURSE trial, a proof-of-concept…
Amgen seeks European approval for teprotumumab in thyroid eye disease
Amgen (NASDAQ: AMGN), a global biotechnology leader, has announced its plans to submit a Marketing Authorization Application (MAA)…